S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
STRO · Sutro Biopharma, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Sutro Biopharma Inc (STRO)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$10.78
-0.75
(-6.50%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$10.78
$10.77
$11.63
52-WEEK RANGE
$10.78
$7.15
$43.85
What's happening
- STRO is down 6.50% today, trading at $10.78. — Live quote
- Volume today (21,574) is well below its 3-month average of 337,640. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-2.33 actual vs. $-2.24 estimated (-4.1%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 6
Buy 12
Hold 1
Sell 1
Strong sell 0
Aggregate ratings for 2026-10-01 (20 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
STRO
-0.26%
vs S&P 500
-13.04%
1-YEAR RETURN
STRO
+1.23%
vs S&P 500
-13.33%
6-MONTH RETURN
STRO
-60.68%
3-MONTH RETURN
STRO
-49.83%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-2.33
Est. $-2.24
MISS -4.1%
2026-04-26 (Q1 2026)
$-2.94
Est. $-3.85
BEAT +23.6%
2026-01-26 (Q4 2025)
$-5.29
Est. $-4.43
MISS -19.4%
2025-10-26 (Q3 2025)
$-6.70
Est. $-4.23
MISS -58.5%
Valuation Measures & Ratios
Enterprise Value4$364.6M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)3.94
Price / Book73.45
EV4 / Revenue7.98
EV4 / EBITDA—
Profit Margin-395.25%
Operating Margin-319.57%
Return on Equity (ROE8)-223.84%
Return on Assets (ROA9)-88.12%
Avg Volume (3M)337,640
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $549.8M | $324.9M | $737.9M | $60.9M | $54.3M |
| P/E | -3.78 | -1.78 | -3.82 | -0.33 | -0.24 |
| Price/Sales | 5.62 | 3.08 | 7.43 | 0.53 | 0.84 |
| Price/Book | -5.32 | -4.86 | -8.46 | -1.90 | -2.10 |
| EV/Revenue | 5.07 | 2.38 | 6.76 | -0.03 | -0.80 |
| EV/EBITDA | -4.72 | -1.76 | -3.72 | — | — |
| ROE | 140.71% | 273.31% | 221.29% | 573.86% | 894.91% |
| ROA | -74.76% | -75.54% | -92.11% | -70.24% | -71.86% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short1,847,453
Change from Prior Settlement-11.02%
% of Float—
Days to Cover (Short Ratio)6.47
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +1.2%. Finnhub market metrics ↗
- Latest SEC filing is Form 4, filed 2026-09-22; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -84.6% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -395.2%. Finnhub fundamentals ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on STRO
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.8M | $14.5M | $9.7M | $63.7M | $17.4M | $8.5M | $25.7M | $13.0M |
| Operating income | -$29.9M | -$29.7M | -$48.5M | -$3.3M | -$68.5M | -$67.9M | -$48.7M | -$56.6M |
| Net income | -$38.5M | -$38.5M | -$56.9M | -$11.5M | -$76.0M | -$48.8M | -$48.0M | -$58.2M |
| EPS (diluted) | $-2.33 | $-2.94 | $-0.67 | $-1.35 | $-9.08 | $-0.59 | $-0.59 | $-0.59 |
| EPS (basic) | $-2.33 | $-2.94 | $-0.67 | $-1.35 | $-9.08 | $-0.59 | $-0.59 | $-0.59 |
| Operating margin | -$304 | -$204 | -$500 | -$5 | -$394 | -$797 | -$189 | -$435 |
| Net margin | -$392 | -$265 | -$587 | -$18 | -$437 | -$573 | -$187 | -$448 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $194.5M | $242.0M | $173.8M | $209.7M | $262.4M | $321.4M | $387.2M | $451.8M |
| Total liabilities | $297.8M | $308.9M | $306.3M | $296.9M | $294.5M | $347.2M | $342.6M | $340.6M |
| Stockholders' equity | -$103.3M | -$66.9M | -$132.5M | -$87.3M | -$32.1M | -$25.8M | $44.6M | $111.2M |
| Total current assets | $175.6M | $221.0M | $150.9M | $182.1M | $231.6M | $287.4M | $343.3M | $405.8M |
| Total current liabilities | $52.9M | $70.8M | $75.1M | $71.9M | $74.2M | $133.0M | $131.9M | $131.3M |
| Cash & equivalents | $54.3M | $73.7M | $58.1M | $65.9M | $64.0M | $106.2M | $190.3M | $174.6M |
| Marketable securities (current) | $110.0M | $128.9M | $83.3M | $101.7M | $141.1M | $142.7M | $126.6M | $213.7M |
| Accounts receivable | $5.8M | $12.5M | $4.0M | $3.9M | $8.0M | $13.6M | $8.6M | $6.7M |
| Marketable securities (non-current) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Property, plant & equipment | $8.4M | $9.4M | $10.6M | $13.3M | $15.0M | $16.8M | $18.2M | $19.0M |
| Other non-current assets | $1.1M | $1.1M | $495.0K | $0 | $50.0K | $85.0K | $7.2M | $7.2M |
| Accounts payable | $3.4M | $5.5M | $7.6M | $7.0M | $4.3M | $8.2M | $10.5M | $6.2M |
| Accrued liabilities | $6.2M | $5.4M | $14.6M | $13.2M | $11.8M | $11.6M | $12.9M | $13.2M |
| Deferred revenue (current) | $6.5M | $9.4M | $10.6M | $9.0M | $12.0M | $69.0M | $69.8M | $72.6M |
| Short-term debt | — | — | — | — | — | — | — | — |
| Other current liabilities | $2.7M | $3.0M | $2.9M | $15.8M | $17.8M | $14.2M | $4.0M | $3.5M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | $1.7M | $1.7M | $1.7M | $1.7M | $1.7M | $1.7M | $1.7M | $1.7M |
| Common stock & paid-in capital | $17.0K | $17.0K | $9.0K | $85.0K | $85.0K | $84.0K | $8.0K | $82.0K |
| Retained earnings | -$1.05B | -$1.02B | -$978.0M | -$931.2M | -$874.3M | -$862.8M | -$786.9M | -$714.4M |
| Accumulated other comprehensive income (loss) | -$58.0K | -$101.0K | $19.0K | $33.0K | -$13.0K | -$9.0K | $39.0K | $106.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$38.3M | -$42.3M | -$26.4M | -$38.2M | -$44.7M | -$67.9M | -$71.7M | -$64.5M |
| Investing cash flow | $19.4M | -$45.3M | $18.7M | $40.0M | $2.6M | -$16.3M | $87.5M | $147.3M |
| Financing cash flow | -$418.0K | $103.1M | -$64.0K | $102.0K | -$60.0K | $66.0K | -$24.0K | $1.0M |
| Capital expenditures | — | — | — | — | — | — | — | — |
| Depreciation & amortization | $1.3M | $1.3M | $1.6M | $1.9M | $1.9M | $1.9M | $1.9M | $1.8M |
| Share-based compensation | $2.0M | $1.6M | $1.7M | $1.6M | $5.3M | $5.5M | $5.9M | $6.5M |
| Change in accounts receivable | -$6.7M | $8.5M | $55.0K | -$4.1M | -$5.6M | $4.9M | $2.0M | -$295.0K |
| Change in accounts payable | -$1.7M | -$2.5M | $575.0K | $2.7M | -$3.8M | -$1.9M | $4.1M | -$123.0K |
| Purchases of investments | $27.8M | $124.7M | $4.0M | $89.9M | $28.6M | $142.4M | $126.0M | $43.2M |
| Share repurchases | — | — | — | — | — | — | — | — |
| Debt issued | — | — | — | — | — | — | — | — |
| Tax withholding on stock comp | $0 | $160.0K | $67.0K | $25.0K | $60.0K | $180.0K | $24.0K | $74.0K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $102.5M | $62.0M | $153.7M | $67.8M | $61.9M |
| Operating income | -$158.4M | -$238.5M | -$89.3M | -$128.9M | -$98.5M |
| Net income | -$191.1M | -$227.5M | -$106.8M | -$119.2M | -$105.5M |
| EPS (diluted) | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 |
| EPS (basic) | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 |
| Operating margin | -$155 | -$384 | -$58 | -$190 | -$159 |
| Net margin | -$186 | -$367 | -$69 | -$176 | -$171 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $173.8M | $387.2M | $470.7M | $406.9M | $341.4M |
| Total liabilities | $306.3M | $342.6M | $321.1M | $189.9M | $88.8M |
| Stockholders' equity | -$132.5M | $44.6M | $149.6M | $217.0M | $252.6M |
| Total current assets | $150.9M | $343.3M | $421.5M | $353.2M | $218.5M |
| Total current liabilities | $75.1M | $131.9M | $93.7M | $66.5M | $41.7M |
| Cash & equivalents | $58.1M | $190.3M | $69.3M | $47.3M | $30.4M |
| Marketable securities (current) | $83.3M | $126.6M | $264.4M | $255.1M | $130.3M |
| Accounts receivable | $4.0M | $8.6M | $36.1M | $7.1M | $12.5M |
| Marketable securities (non-current) | $0 | $0 | $0 | $0 | $68.8M |
| Property, plant & equipment | $10.6M | $18.2M | $21.9M | $24.6M | $22.6M |
| Other non-current assets | $495.0K | $7.2M | $3.6M | $1.9M | $1.7M |
| Accounts payable | $7.6M | $10.5M | $9.4M | $4.8M | $6.0M |
| Accrued liabilities | $14.6M | $12.9M | $14.7M | $13.1M | $11.4M |
| Deferred revenue (current) | $10.6M | $69.8M | $20.7M | $16.8M | $5.5M |
| Short-term debt | — | — | $4.1M | $12.5M | $9.4M |
| Other current liabilities | $2.9M | $4.0M | $3.9M | $3.1M | $2.8M |
| Long-term debt | — | — | $0 | $3.8M | $15.7M |
| Other non-current liabilities | $1.7M | $1.7M | $1.7M | $119.0K | $146.0K |
| Common stock & paid-in capital | $9.0K | $8.0K | $61.0K | $58.0K | $46.0K |
| Retained earnings | -$978.0M | -$786.9M | -$559.4M | -$452.6M | -$333.4M |
| Accumulated other comprehensive income (loss) | $19.0K | $39.0K | $21.0K | -$618.0K | -$314.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$177.2M | -$191.5M | -$111.6M | $3.5M | -$81.7M |
| Investing cash flow | $45.0M | $218.5M | -$3.9M | -$35.0M | -$97.3M |
| Financing cash flow | $44.0K | $94.1M | $137.6M | $48.3M | $3.3M |
| Capital expenditures | — | — | — | — | — |
| Depreciation & amortization | $7.3M | $7.2M | $6.8M | $5.7M | $4.8M |
| Share-based compensation | $14.0M | $24.7M | $24.9M | $26.3M | $23.2M |
| Change in accounts receivable | -$4.6M | -$27.5M | $29.0M | -$5.3M | $6.9M |
| Change in accounts payable | -$2.5M | $706.0K | $4.8M | -$1.2M | $2.7M |
| Purchases of investments | $264.9M | $461.5M | $460.3M | $216.7M | $248.7M |
| Share repurchases | — | — | — | — | $7.0K |
| Debt issued | — | — | — | — | — |
| Tax withholding on stock comp | $332.0K | $509.0K | $490.0K | $463.0K | $987.0K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding STRO as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-03-01 to 2026-09-18
Recent transactions
- Most recent: Gerber Hans-Peter (CHIEF SCIENTIFIC OFFICER) — Option exercise of 3,750 shares on 2026-09-18.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER | Option exercise | 2026-09-18 | 3,750 |
| Chow Gregory K. | CFO | Option exercise | 2026-06-02 | 2,500 |
| Pauling David | Chief Admin. Ofcr. & GC | Option exercise | 2026-03-04 | 675 |
| Chung Jane | Chief Executive Officer | Option exercise | 2026-03-04 | 788 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-18 | Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER | Option exercise | 3,750 | $0.00 |
| 2026-09-18 | Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER | Tax withholding | 1,345 | $15.34 |
| 2026-06-02 | Chow Gregory K. | CFO | Option exercise | 2,500 | $0.00 |
| 2026-03-04 | Pauling David | Chief Admin. Ofcr. & GC | Option exercise | 675 | $0.00 |
| 2026-03-04 | Pauling David | Chief Admin. Ofcr. & GC | Tax withholding | 277 | $21.31 |
| 2026-03-04 | Chung Jane | Chief Executive Officer | Option exercise | 788 | $0.00 |
| 2026-03-04 | Chung Jane | Chief Executive Officer | Tax withholding | 282 | $21.31 |
| 2026-03-02 | Pauling David | Chief Admin. Ofcr. & GC | Option exercise | 2,356 | $0.00 |
| 2026-03-02 | Pauling David | Chief Admin. Ofcr. & GC | Tax withholding | 970 | $20.55 |
| 2026-03-02 | Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER | Option exercise | 2,843 | $0.00 |
| 2026-03-02 | Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER | Tax withholding | 1,170 | $20.55 |
| 2026-03-02 | Chung Jane | Chief Executive Officer | Option exercise | 7,750 | $0.00 |
| 2026-03-02 | Chung Jane | Chief Executive Officer | Tax withholding | 2,779 | $20.55 |
| 2026-03-01 | Pauling David | Chief Admin. Ofcr. & GC | Option exercise | 500 | $0.00 |
| 2026-03-01 | Pauling David | Chief Admin. Ofcr. & GC | Option exercise | 842 | $0.00 |
| 2026-03-01 | Pauling David | Chief Admin. Ofcr. & GC | Tax withholding | 551 | $20.47 |
| 2026-03-01 | Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER | Option exercise | 1,125 | $0.00 |
| 2026-03-01 | Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER | Tax withholding | 463 | $20.47 |
| 2026-03-01 | Chung Jane | Chief Executive Officer | Option exercise | 688 | $0.00 |
| 2026-03-01 | Chung Jane | Chief Executive Officer | Option exercise | 2,500 | $0.00 |
| 2026-03-01 | Chung Jane | Chief Executive Officer | Tax withholding | 1,271 | $20.47 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 00:36 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-22 | 4 | 2026-09-18 | View on SEC.gov → |
| 2026-08-12 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-12 | 8-K | 2026-08-12 | View on SEC.gov → |
| 2026-06-09 | 4 | 2026-06-05 | View on SEC.gov → |
| 2026-06-09 | 4 | 2026-06-05 | View on SEC.gov → |
| 2026-06-09 | 4 | 2026-06-05 | View on SEC.gov → |
| 2026-06-09 | 4 | 2026-06-05 | View on SEC.gov → |
| 2026-06-09 | 4 | 2026-06-05 | View on SEC.gov → |
| 2026-06-09 | 4 | 2026-06-05 | View on SEC.gov → |
| 2026-06-09 | 4 | 2026-06-05 | View on SEC.gov → |
| 2026-06-09 | 4 | 2026-06-05 | View on SEC.gov → |
| 2026-06-08 | 8-K | 2026-06-05 | View on SEC.gov → |
Recent news
Headlines about STRO (Sutro Biopharma, Inc.). Links open the publisher — we don’t host full articles.
-
European shares edge higher as strong earnings offset French unrest worries
The Business Times · 2026-10-21 -
JPMorgan Sees Corning (GLW) Poised to Meet Q3 Guidance Amid Stro
GuruFocus · 2026-10-21 -
Sutro Biopharma doses first patient in STRO-006 phase 1 trial
Investing.com India · 2026-10-21 -
Sutro Biopharma Doses First Patient in Phase 1 Trial of STRO-006 in Advanced Solid Tumors
Quiver Quantitative · 2026-10-21 -
Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors
Yahoo Finance · 2026-10-21 -
Sutro Biopharma Doses First Patient In Its Phase 1 Trial Of STRO-006 In Patients With Range Of Solid Tumors; Initial Clinical Data Expected In H2 2027
Benzinga · 2026-10-21 -
MSCI beats Q3 2026 earnings estimates with stro...
Pluang · 2026-10-20 -
Analysts raise ServiceNow price targets on stro...
Pluang · 2026-10-20
No headlines in this category right now — try “All”.